REG - ReNeuron Group plc - New Senior Appointment

ReNeuronAnnouncement

11/01/2022 07:05

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220111:nRSK9978Xa&default-theme=true

RNS Number : 9978X  ReNeuron Group plc  11 January 2022

ReNeuron Group plc

("ReNeuron" or the "Company")

 

New Senior Appointment Strengthening Exosomes Expertise

 

ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem cell and Exosome
Technologies, announces that Dr Randolph Corteling will re-join ReNeuron on 3
March 2022, heading up the Research team as Vice President of Research and
will report directly into the CEO.

 

Dr Randolph Corteling has 24 years' experience in medical research and drug
discovery, spanning academia, biotechnology and the pharmaceutical industry.
He gained his PhD in Medical and Surgical Sciences at Nottingham University,
followed by three years as a Heart and Stroke Foundation Postdoctoral Fellow
at the University of Calgary, Canada.

 

In 2007 he joined ReNeuron as a senior member of the research team where he
established a deep understanding of stem cell biology and in particular the
role of extracellular vesicles in cell-to-cell communication. In 2011 he was
appointed Head of Cell Biology where he established the first exosome
programmes at ReNeuron, which are now a major commercial opportunity for the
Company. He was later promoted to Head of Research at ReNeuron.

 

Since 2020, Dr Corteling has worked at Evox Therapeutics, a private company
focused on Exosome based therapeutics for rare diseases, where he led their
Disease Biology and Exosome Payloads teams.

 

Olav Hellebø, Chief Executive Officer, commented: "We are delighted to
welcome Randolph back to ReNeuron. His knowledge and experience in the field
of therapeutic exosomes and partnered programmes will be invaluable to us as
we seek to continue to build and expand our exosome platform."

 

 
ENDS

 

Contacts:

 

 ReNeuron                                                 www.reneuron.com/investors (http://www.reneuron.com/investors)
 Olav Hellebø, Chief Executive Officer                    Via Walbrook PR
 Catherine Isted, Chief Financial Officer

 Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)  +44 (0)20 7710 7600

 Ben Maddison, Stewart Wallace

 Allenby Capital Limited (Joint Broker)                   +44 (0)20 3328 5656
 James Reeve/George Payne (Corporate Finance)
 Stefano Aquilino (Sales & Corporate Broking)

 Walbrook PR (Media & Investor Relations)                 +44 (0)20 7933 8780 or reneuron@walbrookpr.com
 Paul McManus, Alice Woodings,                            +44 (0)7980 541 893 / +44 (0)7407 804 654

 Megan Boxall                                              / +44 (0)7788 151 967

 

 

 

About ReNeuron

ReNeuron is a UK based Proprietary Stem Cell and Exosome Technologies company,
harnessing its unique stem cell technologies to develop 'off the shelf'
treatments for disease with significant unmet needs.

 

The Company's lead cell therapy candidate is in clinical development for the
blindness-causing disease, retinitis pigmentosa. The Company has also
out-licensed its CTX programme in stroke disability to Fosun in China.

 

ReNeuron's stem cell derived proprietary Exosome Technology platform offers a
delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins,
small molecules and genes. The Company has a growing number of partner
collaborations with Global Pharma, Biotech and academic partners in this
fast-expanding area of scientific and commercial interest. ReNeuron also has
the ability through its conditionally immortalised induced pluripotent stem
cell (iPSC) platform to make allogeneic tissue cells of choice and has the
potential to produce exosomes with tissue specific targeting ability.

 

ReNeuron's shares are traded on the London AIM market under the symbol
RENE.L.  For further information visit www.reneuron.com
(http://www.reneuron.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBMMBTMTTBTLT